Tyrosine kinase inhibitors (TKI) have become a first-line treatment for chronic myeloid leuakemia (CML). TKIs efficiently target bulk CML cells; however, they are unable to eliminate the leukaemic stem cell (LSC) population that causes resistance and relapse in CML patients. In this study, we assessed the effects of parthenolide (PTL) and dimethyl amino parthenolide (DMAPT), two potent inhibitors of LSCs in acute myeloid leukaemia (AML), on CML bulk and CML primitive (CD34 + lin − ) cells.
proliferation, differentiation and alter cell adhesion. Together, these features characterize CML cells and drive the progression of CML. 5 Diagnosis in 90% of cases occurs at chronic phase (CP), where patients have abnormal cell counts but myeloid cells retain differentiation ability. 6 If not treated, patients progress to an accelerated phase and finally to blast crisis (BC), 6 which is invariably fatal.
Knowledge of the molecular biology of CML has provided the development of tyrosine kinase inhibitors (TKIs), able to directly target Bcr-Abl, and inhibit its downstream activity, offering patients in CP the possibility of achieving remission and prolong survival. TKI's, however, are not able to target LSCs, a rare, quiescent, self-renewing cell population that initiates and sustains CML. 6 Recently, Nieborowska-Skorska and colleagues have reported that LSC from CML patients present high levels of ROS compared to normal primitive cells. 7 This has been related to defects in mitochondria of CML cells, which cause the accumulation of ROS, driving genomic instability and acquired resistance to TKIs. 7 This raises the interest in seeking targets other than Bcr-Abl that may be able to eliminate LSC, which
are not eliminated with current TKI therapies.
Medicinal plants with anti-inflammatory properties are rich reservoirs of bioactive compounds. 8 Parthenolide (PTL) is a sesquiterpene lactone extracted from the plant Tanacetum parthenium, used by folk medicine for anti-inflammatory purposes, arthritis, migraine, as an anticoagulant, and a digestive aid, for centuries. 9 Guzman and collaborators have reported that PTL is able to target activity against LSC in AML. 10 To improve the pharmacological properties of PTL, an orally bioavailable analogue was generated, dimethyl amino parthenolide (DMAPT) that showed similar activity to PTL in AML LSC 11 ; nevertheless, the effect on CML cells, including both primitive primary cells, as well as CML cell lines, is unknown. The mechanism of action of PTL has been reported to rely on a number of pathways, two of which are the inhibition of NF-κB via the alkylation of critical cysteine residues 12 and the induction of ROS by affecting the glutathione system. 13 We present evidence that PTL and DMAPT are able to abrogate bulk CML cells and a primitive CML population (CD34 + lin − ) by a mechanism dependent on ROS induction and NF-κB pathway inhibition. The effect on ROS levels is transitory, reaching a peak at 1 hour of treatment.
In addition, we observed the up-regulation of HMOX-1 which is activated by Nrf2 transcription factor, described as an integrator of cellular stress signals 14 and promotes survival of a fraction of CML cells. These cells demonstrate a cell cycle arrest in G2/M and G0 cell cycle phase, which was accompanied by changes in Cyclin D and A, and down-regulation of CDK2.
| ME TH ODS

| Chemicals and reagents
PTL and DMAPT were kindly provided by Drs. Cesar Compadre and Peter Crooks, respectively (University of Arkansas for Medical Sciences). Both agents were kept at -20 C at 40 mmol/L in DMSO. 
| Cell lines and primary samples
| Immunoblots
Cells were cultured for 6 hours with or without PTL or DMAPT, All data is expressed as Mean ± SEM.
Statistical analysis for each experiment is specified in each figure.
Graph and statistical analysis was done using Graphpad Software.
| RESULTS
| PTL and DMAPT decrease viability of CML bulk and progenitor cells
To assess the effect of PTL and DMAPT on viability, three CML cell lines (K562, Meg-01, and KCL-22) were exposed to increasing concentrations of the compounds for 24 and 48 hours. As a normal control, MNC from NBM were used, as well as AML cell line HL60, previously reported as PTL sensitive. 16 We found a significant decrease in CML cell line viability by trypan blue ( Figure 1A ), the LC50 we observed (7.5 μmol/L at 24 hours, and 5 μmol/L at 48 hours) were similar to the LC50 reported for other leukaemias This is in concordance with a previous report by Li-Weber and colleagues 17 in which PTL at low concentrations (2 μmol/L) induced apoptotic inhibition on T cells. This may also be because of an increase in ROS levels, as an increase in proliferation has been reported by Day and Susuki for fibroblasts exposed to low levels of ROS. + lin − cells exposed to PTL and DMAPT in liquid culture by 24 h and then sub-cultured in methylcellulose for 14 days, stars represent significance with UT group, determined using Dunnet's multiple comparison test. *P < .05 ** P < .01, *** P < .001
| PTL and DMAPT induce cell death in CML cells
To determine if viability loss was related to apoptosis, CML cell lines K562, KCL-22 and Meg-01 were treated with 7.5 and 10 μmol/L PTL or DMAPT, and showed an increase in cell death, compared with untreated ( Figure 2A ,B). The AML cell line HL60 was used as control and showed the highest death level.
To observe this effect in primary samples, MNC from NBM and CML patients (CP and BC), were exposed to PTL and DMAPT. 
| PTL and DMAPT induce Reactive Oxygen
Species (ROS) in CML Cells
Previous reports demonstrated that ROS levels are increased in CML primitive cells. 7 Considering that PTL and DMAPT have been reported as ROS inducers in different cancer models, 21 we assessed 
| PTL and DMAPT inhibit NF-κB pathway in CML cells
PTL and DMAPT have been reported as NF-κB pathway inhibitors, although the molecular mechanisms have not been completely elucidated, a report by García Piñeres and colleagues suggest that PTL blocks NF-κB pathway by alkylation of cysteine residues in p65.
12
Other authors have reported that the mechanism relies on an upstream inhibition of the NF-κB pathway, by inhibiting the activity of IKK. 10 Furthermore, PTL activity has been reported to rely on the alkylation capacity of critical serine residues. 12 To verify if PTL and DMAPT were able to inhibit NF-κB, K562 cells were treated for 6 hours with PTL or DMAPT at 7.5 and 10 μmol/L and p65 total protein localization was assessed by immunofluorescence (Figure 5A ). K562 cells showed an overall decrease in p65 nuclear localization, suggesting pathway inhibition. To verify that nuclear localization inhibition was due to inhibition of p65 phosphorylation, Significance between DCFDA fold change in NBM CD34+ and leukaemia cell lines was determined using an Unpaired Student's T test. **P < .01 and ****P < .0001 F I G U R E 2 PTL and DMAPT induce cell death in CML cells. Leukaemic cell lines and primary samples from CML patients and normal bone marrow were cultured for 24 h at different concentrations of PTL and DMAPT and the cell death index was analysed. A, Shows flow cytometry plots from K562 and Meg-01 CML and HL60 AML cell line (used as a positive control). B, Shows representative plots from 3 primary samples (Normal Bone Marrow and CML from a chronic phase and a blast crisis patient). ex in Untreated conditions or exposed to 7. Significance between treated cells and control in MFI of ROS levels and cell death index was determined using an unpaired Student t-test. *P < .05 **P < .01, ***P < .001, ****P < .0001 activation, the quiescent leukaemic pool has been reported as not sensitive to this inhibition. 27 Recently, our group reported that the G0/G1 phase fraction increases in CML cells after being treated with TKIs, and that this is dependent on nuclear localization of CDK inhibitors p21 and p18. 15 NF-κB has also been reported as a regulator of cell cycle, and it is therefore relevant to all new therapeutic In an effort to understand the role of ROS on cell cycle arrest, the K562 cell line was pre-treated with NAC (a ROS scavenger) for 1 hour at 15 mmol/L. Interestingly, cells pre-treated with NAC indeed changed cell cycle status when they were treated with PTL or DMAPT, indicating that the cell cycle effect is not dependent on ROS increase.
| Cell cycle arrest by PTL and DMAPT is related to cyclin down-regulation
To further evaluate the mechanism behind the cell cycle arrest in Recently, an interest has grown on the ability of parthenolide and its analogue DMAPT, to target malignant populations. Several reports have described effect on neoplastic cells from colorectal, 30 lung and bladder cancer. 31 Of particular importance is their reported capacity to target cancer stem cells, such as acute leukaemia 10 and breast cancer stem cells. 32 The knowledge that different cancers depend on a stem cell-like population to maintain the disease which are resistant to therapy, thus causing relapse and or metastasis, has made it a priority in cancer research to find methodologies to target this population to find better treatments.
The overall data from this work indicate a robust effect of PTL and DMAPT on CML cells. CML cells exposed to PTL and DMAPT loss 50% viability by 24 hours, at a concentration around 7 μmol/L. and proves a key mechanism to be exploited and further studied.
PTL and DMAPT also inhibited phosphorylation and nuclear localization of NF-κB (p65). Interestingly, CML CD34 + lin − cells from chronic phase showed basal phosphorylation and nuclear localization of p65, indicating a basal activity of this transcription factor in the primitive population, suggesting that the NF-κB pathway has biological importance in the CML stem/progenitor compartment, which would be in keeping with the fact that NF-κB inhibition in leukaemia cells has been described as a key factor in achieving LSC eradication in AML by Guzman and colleagues. 35 Nevertheless, on the basis of our results, we propose that the most important mechanism of PTL and Significance between UT and treated cells in proliferation assay was determined using an unpaired Student t-test. Significance between Cell cycle phase was determined using Tukey's multiple comparison test. *P < .05 **P < .01, ***P < .001, ****P < .0001
DMAPT effect on CML cells (without affecting normal cells in a significant manner) is induction of ROS.
One of the hallmarks of CML, is the increase in cell proliferation. 36 TKIs, which directly target the activation of Bcr-Abl, inhibit proliferation of bulk CML cells; however, a fraction of LSC has been shown to enter quiescence and avoid apoptosis. 15 Here, we found that a fraction of CML cells is able to survive PTL and DMAPT treatment. This seems to be linked to cell cycle arrest, which could be dependent on NF-κB inhibition. Interestingly, ROS levels have also been related to cell proliferation. Indeed, in hematopoietic cells they have been linked to FoxO transcription factors, which play an important role in myeloid differentiation. Deletion of FoxO transcription factors in HSC results in increase in ROS levels and differentiation to the myeloid lineage. 34 With this in mind, we expected to find Significance between UT and PTL or DMAPT was determines using an unpaired Student t-test, *P < .05 **P < .01 the arrest on cell cycle to be reversed by NAC pre-treatment; however, to our surprise we found that while cells were consistently rescued from cell death with NAC pre-treatment, they readily suffered a cell cycle arrest that could not be explained by ROS induction.
NF-κB activity in CML has been previously identified as a critical pathway, particularly in imatinib resistant cell lines, 37 and suggested as a therapeutic target. Since we found cell cycle changes to be independent of ROS induction, we sought to further address the mechanism behind cell cycle arrest after sesquiterpene lactone treatment. Thus, we looked into protein levels of cell cycle regulators.
Surviving cells from K562 cell line and CML CD34 + lin − cells after 48 hours treatment showed changes in cyclin D1 and A, p21, and CDK2. K562 cells showed down-regulation of Cyclin D, which is critical in the G1 to S transition. This effect would be consistent with the inhibition of NF-κB as has been reported by Hinz and colleagues, 38 also it is the strongest known link between NF-κB pathway and cell cycle, as mentioned by Joyce and collaborators. 39 We also found a decrease tendency in CDK2 and Cyclin A, which is mostly linked to G2/S cell cycle progression, which would suggest an involvement with the K562 arrest observed in the G2 phase. On the other hand, CD34 + lin − cells from a CML patient showed a marked induction of p21 inhibitor and an increase in CDK2. Interestingly, we did not observe a G2 cell cycle arrest or an S phase burden in this cell population; instead, a cell cycle arrest was strongly observed in the G0/G1 compartment. The absence of a G2 arrest could be explained by an up-regulation of CDK2, however further assessment would be necessary to understand the mechanism behind the cell cycle arrest induced by sesquiterpene lactone.
Taken together, our data show a strong inhibitory effect of PTL and DMAPT on bulk CML cells and on a more primitive CD34 + lin − cell population. We also observed that PTL-induced cell death is accompanied by cell cycle arrest in surviving cells. Our findings indicate that cell cycle arrest we observed after PTL and DMAPT treatment is ROS independent, and changes in cell cycle regulators would be consistent with NF-κB inhibition. We speculate that evading cell cycle arrest could increase and potentiate PTL and DMAPT effect on the CML model. Finally, it is important to comment that it is necessary to consider an in vivo approach to consider PTL and DMAPT as selective molecules to eliminate CML primitive cells.
